SGIOY Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 10:26):

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan...

Stats
Today's Volume	7 418.00
Average Volume	45 314.00
Market Cap	13.10B
EPS	$0 ( 2024-01-29 )
Next earnings date	( $0 ) 2024-05-08
Last Dividend	$0.121 ( 2021-09-28 )
Next Dividend	$0 ( N/A )
P/E	13.77
ATR14	$0.0280 (0.24%)

Volume Correlation

Long: -0.17 (neutral)

Short: 0.32 (neutral)

Signal:(67.95) Neutral

Shionogi & Co., Ltd. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Shionogi & Co., Ltd. Correlation - Currency/Commodity

0.69
( moderate )

0.47
( neutral )

0.00
( neutral )

0.80
( moderate )

0.30
( neutral )

0.76
( moderate )

Shionogi & Co., Ltd. Financials

Annual	2023
Revenue:	$426.68B
Gross Profit:	$356.58B (83.57 %)
EPS:	$621.31

Q3	2023
Revenue:	$106.28B
Gross Profit:	$91.76B (86.34 %)
EPS:	$31.74

Q2	2023
Revenue:	$121.23B
Gross Profit:	$106.47B (87.82 %)
EPS:	$41.02

Q1	2023
Revenue:	$109.31B
Gross Profit:	$96.19B (88.00 %)
EPS:	$36.16

Financial Reports:

No articles found.

Shionogi & Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Shionogi & Co., Ltd. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.97 - Stable (19.36%)

Information

First Dividend	$0.124	2021-03-29
Last Dividend	$0.121	2021-09-28
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.245	--
Avg. Dividend % Per Year	0.00%	--
Score	3.75	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.97
Div. Directional Score	9.09	--

Next Divdend (Est)
(2024-06-21)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

3.75

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
SATLF	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
FUPBY	Ex Dividend Knight	2023-05-04	Annually	0.00%
AILLO	Ex Dividend Knight	2023-07-14	Semi-Annually	0.00%
WRTBY	Ex Dividend Knight	2023-09-12	Semi-Annually	0.00%
MHGVY	Ex Dividend Knight	2023-09-01	Quarterly	0.00%
CNTHO	Ex Dividend Knight	2023-09-07	Quarterly	0.00%
SOUHY	Ex Dividend Junior	2023-09-14	Annually	0.00%
HHULY	Ex Dividend Junior	2023-06-15	Annually	0.00%
ATLCY	Ex Dividend Knight	2023-10-19	Semi-Annually	0.00%
NUBC	Ex Dividend Knight	2023-09-07	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.363	1.500	2.73	4.10	[0 - 0.5]
returnOnAssetsTTM	0.114	1.200	6.21	7.46	[0 - 0.3]
returnOnEquityTTM	0.132	1.500	9.64	10.00	[0.1 - 1]
payoutRatioTTM	0.288	-1.000	7.12	-7.12	[0 - 1]
currentRatioTTM	6.57	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	5.74	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.47	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00724	-1.500	9.88	-10.00	[0 - 0.6]
interestCoverageTTM	16.34	1.000	5.06	5.06	[3 - 30]
operatingCashFlowPerShareTTM	445.43	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	362.35	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.00826	-1.500	9.97	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.851	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.383	1.000	4.35	4.35	[0.1 - 0.6]
cashFlowToDebtRatioTTM	13.06	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.313	0.800	-1.249	-0.999	[0.5 - 2]
Total Score				12.21

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	3.39	1.000	9.76	0	[1 - 100]
returnOnEquityTTM	0.132	2.50	9.77	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	362.35	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.00474	1.500	9.88	0	[0 - 0.4]
operatingCashFlowPerShareTTM	445.43	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.288	1.500	7.12	-7.12	[0 - 1]
pegRatioTTM	-0.00227	1.500	-3.35	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.302	1.000	4.94	0	[0.1 - 0.5]
Total Score				5.97

Shionogi & Co., Ltd.

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.